drugset / Trial / NCT03776851

Erythropoietin in Hemolytic Uremic Syndrome

NCT03776851 ↗

Phase 4 Completed 24 enrolled Hospital General de Niños Pedro de Elizalde
RandomizedParallel-groupOpen-labelSupportive care

Summary

This study will evaluate the impact of early administration of erythropoietin in the number of red blood cell transfusions in children with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome (STEC-HUS).

Timeline

Start
2019-01-01
Primary completion
2020-12-30
Completion
2020-12-30

Outcome

Missed primary endpoint

paper Median number of RBC transfusions was similar between groups (1.5, p = 0.76). PMID 35166922 ↗

paper In children with STEC-HUS, the administration of rHuEPO did not reduce the number of RBC transfusions. PMID 35166922 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 50 iu/kg Subcutaneous